Brightlands Venture Partners — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
PL BioScience develops human platelet-based cell culture media that promote cell growth, used in biotechnology research and cell culture applications.
BiotechNew Materials
Dr. Hatim Hemeda(Founder & CEO)
Co-investorsAvant BioTechVision FondsBetter Ventures
Vivalyx develops organ revitalization technology aimed at improving organ vitality for transplantation.
BiotechHealthtechMedical DevicesAachen, DE
Benedict Doorschodt(Founder)in
Co-investorsTechVision FondsBessemer Venture PartnersGOOSE CapitalSpringboard Health Angels
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.